Literature DB >> 19239332

High dose rate versus low dose rate brachytherapy in the treatment of tongue carcinoma - a radiobiological study.

J Petera1, P Matula, P Paluska, I Sirak, Z Macingova, L Kasaova, T Frgala, M Hodek, M Vosmik.   

Abstract

UNLABELLED: Low dose rate (LDR) brachytherapy is a well established treatment for the early stages of tongue cancer. High dose rate (HDR) afterloading devices have replaced LDR brachytherapy in many radiotherapy departments, but the effect and safety of HDR brachytherapy in comparison with LDR brachytherapy for interstitial applications is an unresolved question. The aim of our radiobiological study was to utilize dose volume histiograms from patients treated in our institution to simulate the risk of complication of LDR and HDR brachytherapy. Normal tissue complication probabilities (NTCP) of acute mucositis, late mucosal necrosis and osteoradionecrosis of two HDR brachytherapy schedules (18 x 3 Gy bid and 10 x 6 Gy bid) and of LDR brachytherapy with identical tumor control probability were compared using data from 8 brachytherapy applications. A linear quadratic (LQ) model was used to calculate the biologically equivalent doses, the effective volume method of Kutcher and Burman and Lyman's model was used to calculate NTCP. The Student's two-tailed test was used for statistical analysis. For 18 x 3 Gy bid the risk of acute mucositis and of late mucosal necrosis was 1.48 and 1.66 times higher with HDR in comparison with LDR brachytherapy. For 10 x 6 Gy bid the risk of acute mucositis, mucosal necrosis and osteoradionecrosis was 1.3, 3.44 and 13.18 times higher with HDR brachytherapy. All differences were statistically highly significant. Our radiobiological study supported the hypothesis that HDR has a higher risk of complication in comparison with LDR brachytherapy for the same tumor control probability. KEYWORDS: tongue cancer, brachytherapy, low dose rate, high dose rate.

Entities:  

Mesh:

Year:  2009        PMID: 19239332     DOI: 10.4149/neo_2009_02_163

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  Evaluation of neuropathic pain occurring after high-dose-rate interstitial brachytherapy of oral tongue.

Authors:  Vijai Simha; Suresh C Sharma; Rakesh Kapoor; Chirag K Ahuja; Arun S Oinam; Sushmita Ghoshal
Journal:  J Contemp Brachytherapy       Date:  2015-04-01

Review 2.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

3.  Adjuvant high-dose-rate brachytherapy in the management of oral cavity cancers: 5 years of experience in Iran.

Authors:  Ali Kazemian; Mohammad Babaei; Marzieh Lashkari; Reza Ghalehtaki; Ata Garajei; Maziar Motiee-Langroudi; Ahmadreza Sebzari; Ramin Jaberi; Soraya Gholami; Somayyeh Babaloui; Mahdi Aghili
Journal:  J Contemp Brachytherapy       Date:  2017-08-30

4.  High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art - a single institute experience.

Authors:  Rajendra Bhalavat; Manish Chandra; Vibhay Pareek; Lalitha Nellore; Karishma George; P Nandakumar; Pratibha Bauskar
Journal:  J Contemp Brachytherapy       Date:  2017-04-13

5.  Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer.

Authors:  Hironori Akiyama; Ken Yoshida; Kimishige Shimizutani; Hideya Yamazaki; Masahiko Koizumi; Yasuo Yoshioka; Naoya Kakimoto; Shumei Murakami; Souhei Furukawa; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2012-06-28       Impact factor: 2.724

Review 6.  High dose rate brachytherapy for oral cancer.

Authors:  Hideya Yamazaki; Ken Yoshida; Yasuo Yoshioka; Kimishige Shimizutani; Souhei Furukawa; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2012-11-23       Impact factor: 2.724

7.  High dose rate versus low dose rate brachytherapy for oral cancer--a meta-analysis of clinical trials.

Authors:  Zhenxing Liu; Shengyun Huang; Dongsheng Zhang
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.